Christine B. Hunter, R.N., CCRC

Instructor of Neurology

Graduate School

ADN (1990) Houston Community College

Clinical Interests

Movement disorders including Parkinson's disease, essential tremor, dystonia, Tourette's syndrome and Huntington's disease.

Research Interests

Experimental therapeutics and genetics of movement disorders.

Publications

Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an Increasingly Recognized Cause of Tardive Dyskinesia. J Clin Pharmacol 2008;:.
Deng H, Le WD, Hunter CB, Mejia N, Xie WJ, Jankovic J. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol 2007;64:421-4.
Kenney C, Diamond A, Mejia N, Davidson A, Hunter C, Jankovic J. Distinguishing psychogenic and essential tremor. J Neurol Sci 2007;263:94-9.
Kenney C, Hunter C, Davidson A, Jankovic J. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007;22:03-Oct.
Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-7.
Kenney C, Simpson R, Hunter C, Ondo W, Almaguer M, Davidson A, Jankovic J. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg 2007;106:621-5.
Deng H, Le W, Guo Y, Hunter CB, Xie W, Huang M, Jankovic J. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci 2006;251:102-6.
Deng H, Le WD, Hunter CB, Ondo WG, Guo Y, Xie WJ, Jankovic J. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol 2006;63:273-7.
Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006;67:2233-5.
Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine?. Clin Neuropharmacol 2006;29:259-64.
Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2006;:.
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40.
Ondo WG, Hunter C. Flumazenil, a GABA antagonist, may improve features of Parkinson's disease. Mov Disord 2003;18:683-5.
Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002;8:271-6.
Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002;17:1031-5.
Xu PY, Liang R, Jankovic J, Hunter C, Zeng YX, Ashizawa T, Lai D, Le WD. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology 2002;58:881-4.

Poster Presentations

Jimenez-Shahed J, Hunter CB, Jankovic J. Acamprosate Improves Impulse Control Disorders in Parkinson’s Disease. American Academy of Neurology (AAN), 60th Annual Meeting in Chicago, Illinois (April 12-19, 2008).
Hunter CB, Kenney K, Mejia N, Davidson A, Jankovic J. Medications Associated with the Onset of Tardive Dyskinesia. American Academy of Neurology (AAN), 59th Annual Meeting in Boston, Massachusetts (April 28 - May 5, 2007).
Hunter CB, Tan EK, Lee J, Shinawi LM, Fook-Chong S, Jankovic J. Comparing Knowledge and Attitudes towards Genetic Testing in Parkinson’s Disease in an American and Asian Population. Movement Disorder Society (MDS), 10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan (Oct. 30 - Nov. 2, 2006).
Kenney C, Diamond AL, Mejia N, Hunter CB, Jankovic J. Clinical Features that Distinguish Psychogenic and Essential Tremor. Movement Disorder Society (MDS), 10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan (Oct. 30 - Nov. 2, 2006).
Kenney C, Hunter CB, Davidson A, Jankovic J. Short-Term Effects of Tetrabenazine on Chorea Associated with Huntington Disease. Movement Disorder Society (MDS), 10th International Congress of Parkinson's Disease and Movement Disorders in Kyoto, Japan (Oct. 30 - Nov. 2, 2006). [Previously Presented]
Kenney C, Hunter CB, Davidson A, Jankovic J. Short-Term Effects of Tetrabenazine on Chorea Associated with Huntington Disease. American Neurological Association (ANA), 131st Annual Meeting in Chicago, Illinois (Oct. 8-11, 2006).
Kenney C, Simpson Jr RK, Hunter CB, Ondo WG, Almaguer M, Davidson A, Jankovic J. Short-Term and Long-Term Safety of Deep Brain Stimulation in the Treatment of Movement Disorders. American Neurological Association (ANA), 131st Annual Meeting in Chicago, Illinois (Oct. 8-11, 2006).
Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine: Does Prior History of Depression Preclude this Drug as a Treatment Option?. Movement Disorder Society (MDS), 9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, Louisiana (March 5-8, 2005).
Jankovic J, Hunter C, Atassi MZ, Dolimbek BZ, Dolimbek GS, and BOS Research Group. Botulinum Toxin Type B Observational Study (BOS). Movement Disorder Society (MDS), 9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, Louisiana (March 5-8, 2005).
Mejia N, Vuong KD, Hunter C, Jankovic J. Medications Associated with the Onset of Tardive Dyskinesia. Movement Disorder Society (MDS), 9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, Louisiana (March 5-8, 2005).
Mejia NI, Hunter C, Flores K, Ondo WG. A Pilot Study of the Clinical Efficacy and Safety of Memantine for Huntington's Disease. Movement Disorder Society (MDS), 9th International Congress of Parkinson's Disease and Movement Disorders in New Orleans, Louisiana (March 5-8, 2005).
Jankovic J, Hunter CB, Vuong KD. Safety and Efficacy of Tetrabenazine in the Treatment of Huntington's Disease and Other Choreas. Etiology, Pathogenesis, and Treatment of Parkinson's Disease and Other Movement Disorders, 18th Annual Symposium in Toronto, Canada (Oct. 3, 2004).
Hunter C, Vuong KD, Mejia N, Jankovic J. Tetrabenazine, a Monoamine Depleter, Effective in the Treatment of Tourette Syndrome. Movement Disorder Society (MDS), 8th International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy (June 13-17, 2004).
Jankovic J, Hunter C, Mejia N, Vuong KD. Tetrabenazine: Effective Treatment for Tardive Dyskinesia. Movement Disorder Society (MDS), 8th International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy (June 13-17, 2004).
Vuong KD, Hunter C, Mejia N, Jankovic J. Safety and Efficacy of Tetrabenazine in Childhood Hyperkinetic Movement Disorders. Movement Disorder Society (MDS), 8th International Congress of Parkinson's Disease and Movement Disorders in Rome, Italy (June 13-17, 2004).
Hunter CB, Vuong KD, Jankovic J. Long-Term Tolerability of Tetrabenazine in the Treatment of Hyperkinetic Movement Disorders. American Academy of Neurology (AAN), 56th Annual Meeting in San Francisco, California (April 24 - May 1, 2004).
Jankovic J, Hunter CB, Vuong KD. Tetrabenazine in the Treatment of Chorea. American Society for Experimental NeuroTherapeutics (ASENT), 6th Annual Meeting in Bethesda, Maryland (March 11-13, 2004).
Ondo WG, Hunter CB, Moore W. A Double Blind Placebo Controlled Parallel Trial of Botulinum Toxin B (Myobloc™) for the Treatment of Sialorrhea in Parkinson Disease. American Academy of Neurology (AAN), 55th Annual Meeting in Honolulu, Hawaii (March 29 - April 5, 2003).
Hunter CB, Wang A, Vuong KD, Jankovic J. Age-Related Tolerability of Tetrabenazine. Movement Disorder Society (MDS), 7th International Congress of Parkinson's Disease and Movement Disorders in Miami, Florida (Nov. 10-14, 2002).
Hunter CB, Wang A, Vuong KD, Jankovic J. Tetrabenazine in the Treatment of Tourette Syndrome. Movement Disorder Society (MDS), 7th International Congress of Parkinson's Disease and Movement Disorders in Miami, Florida (Nov. 10-14, 2002).
Ondo WG, Hunter C, Vuong KD, Jankovic J. Olanzapine Treatment for Dopaminergic Induced Hallucinations. Movement Disorder Society (MDS), 6th International Congress of Parkinson's Disease and Movement Disorders in Barcelona, Spain (June 11-15, 2000).

Contact Information

Christine B. Hunter, R.N., CCRC
Department of Neurology
Baylor College of Medicine
One Baylor Plaza, MS NB302
Houston, Texas 77030

Tel: 713-798-3951
Fax: 713-798-6808
Email: